Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 43, Issue 12, 2002, Pages 2413-2415

  Liu, Nina Shih ^a   O'Brien, S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Chronic myelogenous leukemia in blast phase; Imatinib mesylate; Spontaneous reversion

Indexed keywords

ANTIHISTAMINIC AGENT; BCR ABL PROTEIN; CD33 ANTIGEN; CD34 ANTIGEN; HYDROXYUREA; IMATINIB; INTERFERON; MICROSOMAL AMINOPEPTIDASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLAST CELL CRISIS; BLAST TRANSFORMATION; BONE MARROW SUPPRESSION; CANCER PATIENT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CHRONICITY; CYTOGENETICS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; LEUKEMIA REMISSION; PRIORITY JOURNAL; RASH; CHEMICALLY INDUCED DISORDER; CHROMOSOME ANALYSIS; DRUG RESISTANCE; IMMUNOPHENOTYPING; PATHOLOGY;

AGED; BLAST CRISIS; CYTOGENETIC ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROXYUREA; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0036890851     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/1042819021000040152     Document Type: Article

References (20)

1. Faderl, S., Talpaz, M., Estrov, Z. and Kantarjian, H. (1999) "Chronic myelogenous leukemia: Biology and therapy", Annals of Internal Medicine 131(3), 207-219.
2. Sawyer, C. (1999) "Medical progress: Chronic myelogenous leukemia", New England Journal of Medicine 340(17), 1330-1340.
3. Gratwold, A. and Hermans, J. (1996) "Allogeneic bone marrow transplant for chronic myeloid leukemia. Working party chronic leukemia of the European Group for Blood and Marrow Transplantation (EBMT)", Bone Marrow Transplantation 17(Suppl. 3), S7-S9.
4. Gratwold, A., Hermans, J., Goldman, J., Arcese, W., Carreras, E., Devergie, A., Frassoni, F., Gahrton, G., Kolb, H., Niederwieser, D., Ruutu, T., Vernant, J., de Witte, T. and Apperley, A. (1998) "Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation", Lancet 352, 1087-1092.
5. Van Rhee, F., Szydlo, R., Hermans, J., Devergie, A., Frassoni, F., Arcese, W., de Witte, T., Kolb, H., Niederwiser, D., Jacobsen, N., Gahrton, G., Bandini, G., Carreras, E., Bacigalupo, A., Michallet, M., Ruutu, T., Reiffers, J., Goldman, J., Apperley, J. and Gratwold, A. (1997) "Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the chronic leukemia working party of the European Group for Blood and Bone Marrow Transplantation (EBMT)", Bone Marrow Transplantation 20, 553-560.
6. The Italian Cooperative Study Group on Chronic Myeloid Leukemia (1994) "Interferon alpha-2a as compared to conventional chemotherapy for the treatment of chronic myeloid leukemia", New England Journal of Medicine 330(12), 820-825.
7. Kantarjian, H., O'Brien, S., Anderlini, P. and Talpaz, M. (1996) "Treatment of chronic myelogenous leukemia: Current status and investigational options", Blood 87(8), 3069-3081.
8. Kantarjian, H., Smith, T., O'Brien, S., Beran, M., Pierce, S. and Talpaz, M. (1995) "Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy", Annals of Internal Medicine 122(4), 254-261.
9. Chronic Myeloid Leukemia Trialists' Collaborative Group (1997) "Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials", Journal of the National Cancer Institute 89(21), 1616-1620.
10. Goldman, J. and Melo, J. (2001) "Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine 344(14), 1084-1086.
11. Savage, D. and Antman, K. (2002) "Drug therapy: Imatinib mesylate-a new oral targeted therapy", New England Journal of Medicine 346(9), 683-693.
12. Druker, B., Talpaz, M., Resta, D., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H., Capdeville, R., Ohno-Jones, S. and Sawyers, C. (2001) "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia", New England Journal of Medicine 344(14), 1031-1037.
13. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., Talpaz, M. and Druker, B. (2002) "Hematologic and cytogenetic response to imatinib mesylate in chronic myelogenous leukemia", New England Journal of Medicine 346(9), 645-652.
14. Sacchi, S., Kantarjian, H., O'Brien, S., Cortes, S., Rios, M., Giles, F., Beran, M., Koller, C., Keating, M. and Talpaz, M. (1999) "Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients", Cancer 86(12), 2632-2641.
15. Druker, B., Sawyers, C., Kantarjian, H., Resta, D., Reese, S., Ford, J., Capdeville, R. and Talpaz, M. (2001) "Activity of specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia an acute lymphoblastic leukemia with the Philadelphia chromosome", New England Journal of Medicine 344(14), 1038-1042.
16. Gorre, M., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. and Sawyers, C. (2001) "Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification", Science 293, 876-880.
17. Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R. and Gambacorti-Passerini, C. (2000) "Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification", Blood 95(5), 1758-1766.
18. Gambacorti-Passerini, C., Barni, R., Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., Pioltelli, P., Pogliani, E., Corneo, G., Fomelli, F. and D'Incalci, M. (2000) "Role of alpha-1 acid glycoprotein in the in vivo resistance of human BCR-ABL leukemic cells to ABL inhibitor STI571", Journal of the National Cancer Institute 92(20), 1641-1650.
19. Mahon, F., Deininger, M., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J. and Melo, J. (2000) "Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance", Blood 96(3), 1070-1079.
20. Weisberg, E. and Griffin, J. (2000) "Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR-ABL transformed hematopoietic cell lines", Blood 95(11), 3498-3505.